Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 10,627 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-RPGR; Genetic
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions: oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 30
States / cities: Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Von Willebrand Factor Deficiency
Interventions: Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 12
States / cities: Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more

Conditions: Spinal Cord Injuries
Interventions: Vibrating Dumbbell, Standard Dumbbell; Device
Lead sponsor: Alicia Koontz; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Castration Resistant Metastatic Prostate Cancer
Interventions: Testosterone cypionate, Enzalutamide, Testosterone Enanthate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions: Oxaliplatin, Leucovorin Calcium, Fluorouracil, Carboplatin, Paclitaxel, Positron Emission Tomography, Computed Tomography, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 68
States / cities: Mountain View, California • Palo Alto, California • San Francisco, California + 46 more

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 75 Years and older
Enrollment: 3,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 81
States / cities: Fort Smith, Arkansas • Los Alamitos, California • Sacramento, California + 70 more

Conditions: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Interventions: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only); Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Breast Cancer, Depression, Fatigue, Sleep Disorders
Interventions: Metformin, Placebo; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 252
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 185 more

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions: Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 36
States / cities: Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more

Conditions: Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leukemia, Myeloid, Chronic Phase
Interventions: Imatinib mesylate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 50
States / cities: Mobile, Alabama • Berkeley, California • Campbell, California + 35 more

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: Migraine
Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 38
States / cities: San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more

Conditions: Irradiation; Adverse Effect
Interventions: Minocycline; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Huntington Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Baltimore, Maryland • Bethesda, Maryland • Pittsburgh, Pennsylvania + 1 more

Conditions: Cystic Fibrosis, Contraception, Physician-Patient Relations, Pregnancy Complications
Interventions: MyVoice:CF; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions: cabozantinib; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Adverse Effect of MRI on an Implanted Pacemaker Lead, Adverse Effect of MRI on an Implanted Pacemaker
Interventions: Accent MRI system (lead safety), Accent MRI system (with MRI scan); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 66
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 57 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Jose, California + 10 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 84
States / cities: Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more

Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 130
States / cities: Tucson, Arizona • Burbank, California • La Jolla, California + 92 more

Conditions: Gestational Diabetes
Interventions: Glyburide, Continuous glucose monitor; Drug · Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pharmacokinetics, Safety Issues, Bleeding
Interventions: IPM Ring-105, IPM Ring-106; Combination Product
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Portland, Oregon • Pittsburgh, Pennsylvania

Search by objective public record fields.

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Low VW Activity in Adolescent HMB

Effect of Vibration Exercise on Upper Limb Strength, Function, and Pain

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

SILVER-AMI: Outcomes in Older Persons With Heart Attacks

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

Minocycline Therapy for Management of Adverse Radiation Effects

Making Sense of a Positive Genetic Test Result for Huntington Disease

MyVoice:CF Decision Aid for Women With Cystic Fibrosis

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead

Effect of Interleukin-2 on HIV Treatment Interruption

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel